ArticleMolecular medicine (Cambridge, Mass.)2025
Targeting LINC02544/miR-497-5p/CAPRIN1 axis via exosome-based siRNA to overcome immunotherapy resistance in triple-negative breast cancer.
Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Targeting lncRNAs to Overcome Cancer Therapy Resistance: Advances in RNA Therapeutics and Delivery Strategies.Cancers · 2026Review
- Exosome-mediated siRNA delivery in cancer: Loading strategies, targeting approaches, and therapeutic outcomes.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- In vivo inhibition of TDO2 in fibroids results in widespread alteration in the tumor transcriptome.Clinical science (London, England : 1979) · 2026Article
- Small interfering RNA (siRNA)-based targeting breast cancer therapy.Discover oncology · 2026Review
- siRNA Nanoparticle Delivery Strategies and Clinical Trial Advances in Tumor Therapy.International journal of molecular sciences · 2026Review
- Orchestrating Tumor Metastasis: Exosomes as Master Regulators of the Local and Distant Microenvironment.International journal of biological sciences · 2026Review
- Advances in immunotherapy for thyroid malignancies: from molecular targets to clinical outcomes.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTriple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by the absence of estrogen receptor, progesterone receptor, and HER2 expression, leading to poor clinical outcomes and resistance to targeted therapies. Immunotherapy has shown limited success due to the development of resistance mechanisms. This study aimed to investigate the role of long non-coding RNA LINC02544 in mediating immunotherapy resistance through regulation of the miR-497-5p/CAPRIN1 axis in TNBC.
methodsBioinformatic analyses of TCGA and GEO databases were performed to assess LINC02544 and miR-497-5p expression in TNBC tissues. In vitro experiments evaluated the regulatory effects of LINC02544 on miR-497-5p and CAPRIN1 expression, as well as TNBC cell proliferation and migration. Exosome-mediated siRNA delivery targeting LINC02544 (exo/si-LINC02544) was tested both in vitro and in vivo in combination with a PD-1 inhibitor in a TNBC mouse model.
resultsLINC02544 was significantly overexpressed in TNBC, while miR-497-5p was downregulated. In vitro, LINC02544 silencing via exo/si-LINC02544 reduced CAPRIN1 levels, upregulated miR-497-5p, and inhibited TNBC cell proliferation and migration. In vivo, exo/si-LINC02544 combined with PD-1 blockade suppressed tumor growth and enhanced immune cell infiltration.
conclusionsTargeting the LINC02544/miR-497-5p/CAPRIN1 axis with exosome-based siRNA delivery represents a promising therapeutic strategy to overcome immunotherapy resistance in TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.